Academic Journal
أعرض في EDS

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges

التفاصيل البيبلوغرافية
العنوان: Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
المؤلفون: Alessandro Poggi, Maria Raffaella Zocchi
المصدر: Molecular Therapy: Oncolytics, Vol 24, Iss , Pp 26-42 (2022)
بيانات النشر: Elsevier, 2022.
سنة النشر: 2022
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: natural killer cells, T lymphocytes, KIR, CLIR, PD1, PDL1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: The discovery of immune checkpoints (ICs) and the development of specific blockers to relieve immune effector cells from this inhibiting mechanism has changed the view of anti-cancer therapy. In addition to cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed death 1 (PD1), classical ICs of T lymphocytes and recently described also on a fraction of natural killer (NK) cells, several NK cell receptors, including killer immunoglobulin-like inhibitory receptors (KIRs) and NGK2A, have been recognized as checkpoint members typical of the NK cell population. This offers the opportunity of a dual-checkpoint inhibition approach, targeting classical and non-classical ICs and leading to a synergistic therapeutic effect. In this review, we will overview and discuss this new perspective, focusing on the most relevant candidates for this role among the variety of potential NK ICs. Beside listing and defining classical ICs expressed also by NK cells, or non-classical ICs either on T or on NK cells, we will address their role in NK cell survival, chronic stimulation or functional exhaustion, and the potential relevance of this phenomenon on anti-tumor immune response. Furthermore, NK ICs will be proposed as possible new targets for the development of efficient combined immunotherapy, not forgetting the relevant concerns that may be raised on NK IC blockade. Finally, the impact of epigenetic drugs in such a complex therapeutic picture will be briefly addressed.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2372-7705
Relation: http://www.sciencedirect.com/science/article/pii/S2372770521001650; https://doaj.org/toc/2372-7705
DOI: 10.1016/j.omto.2021.11.016
URL الوصول: https://doaj.org/article/a051b0a610614576a2dc3e8c0ab42baa
رقم الانضمام: edsdoj.051b0a610614576a2dc3e8c0ab42baa
قاعدة البيانات: Directory of Open Access Journals
ResultId 1
Header edsdoj
Directory of Open Access Journals
edsdoj.051b0a610614576a2dc3e8c0ab42baa
967
3
Academic Journal
academicJournal
967.350158691406
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.051b0a610614576a2dc3e8c0ab42baa&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doaj.org/article/a051b0a610614576a2dc3e8c0ab42baa [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=23727705&ISBN=&volume=24&issue=26-42&date=20220301&spage=26&pages=26-42&title=Molecular Therapy: Oncolytics&atitle=Natural%20killer%20cells%20and%20immune-checkpoint%20inhibitor%20therapy%3A%20Current%20knowledge%20and%20new%20challenges&id=DOI:10.1016/j.omto.2021.11.016 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Alessandro+Poggi%22">Alessandro Poggi</searchLink><br /><searchLink fieldCode="AR" term="%22Maria+Raffaella+Zocchi%22">Maria Raffaella Zocchi</searchLink> )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Molecular Therapy: Oncolytics, Vol 24, Iss , Pp 26-42 (2022) )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier, 2022. )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22natural+killer+cells%22">natural killer cells</searchLink><br /><searchLink fieldCode="DE" term="%22T+lymphocytes%22">T lymphocytes</searchLink><br /><searchLink fieldCode="DE" term="%22KIR%22">KIR</searchLink><br /><searchLink fieldCode="DE" term="%22CLIR%22">CLIR</searchLink><br /><searchLink fieldCode="DE" term="%22PD1%22">PD1</searchLink><br /><searchLink fieldCode="DE" term="%22PDL1%22">PDL1</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The discovery of immune checkpoints (ICs) and the development of specific blockers to relieve immune effector cells from this inhibiting mechanism has changed the view of anti-cancer therapy. In addition to cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed death 1 (PD1), classical ICs of T lymphocytes and recently described also on a fraction of natural killer (NK) cells, several NK cell receptors, including killer immunoglobulin-like inhibitory receptors (KIRs) and NGK2A, have been recognized as checkpoint members typical of the NK cell population. This offers the opportunity of a dual-checkpoint inhibition approach, targeting classical and non-classical ICs and leading to a synergistic therapeutic effect. In this review, we will overview and discuss this new perspective, focusing on the most relevant candidates for this role among the variety of potential NK ICs. Beside listing and defining classical ICs expressed also by NK cells, or non-classical ICs either on T or on NK cells, we will address their role in NK cell survival, chronic stimulation or functional exhaustion, and the potential relevance of this phenomenon on anti-tumor immune response. Furthermore, NK ICs will be proposed as possible new targets for the development of efficient combined immunotherapy, not forgetting the relevant concerns that may be raised on NK IC blockade. Finally, the impact of epigenetic drugs in such a complex therapeutic picture will be briefly addressed. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article )
Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2372-7705 )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://www.sciencedirect.com/science/article/pii/S2372770521001650; https://doaj.org/toc/2372-7705 )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1016/j.omto.2021.11.016 )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/a051b0a610614576a2dc3e8c0ab42baa" linkWindow="_blank">https://doaj.org/article/a051b0a610614576a2dc3e8c0ab42baa</link> )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.051b0a610614576a2dc3e8c0ab42baa )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1016/j.omto.2021.11.016 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 17 [StartPage] => 26 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => natural killer cells [Type] => general ) [1] => Array ( [SubjectFull] => T lymphocytes [Type] => general ) [2] => Array ( [SubjectFull] => KIR [Type] => general ) [3] => Array ( [SubjectFull] => CLIR [Type] => general ) [4] => Array ( [SubjectFull] => PD1 [Type] => general ) [5] => Array ( [SubjectFull] => PDL1 [Type] => general ) [6] => Array ( [SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens [Type] => general ) [7] => Array ( [SubjectFull] => RC254-282 [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Alessandro Poggi ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Maria Raffaella Zocchi ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 03 [Type] => published [Y] => 2022 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 23727705 ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 24 ) [1] => Array ( [Type] => issue [Value] => 26-42 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Molecular Therapy: Oncolytics [Type] => main ) ) ) ) ) ) )
IllustrationInfo